RESEARCH TRIANGLE PARK, NC--Zofran Tablets (ondansetron), from
Cerenex Pharmaceuticals, Division of Glaxo Inc., has received
FDA approval for a new indication--the prevention of radiation-induced
nausea and vomiting. The oral agent, a 5-HT3 antagonist, is currently
marketed for prevention of emesis in cancer patients receiving
moderately emetogenic chemotherapy.
The specific recommendation is for patients receiving either total
body irradiation, single high-dose fraction, or daily fractions
to the abdomen. The recommended oral dosage for the new indication
is one 8 mg Zofran Tablet given three times a day. In radiotherapy
trials, the most commonly reported side effects of Zofran Tablets
were constipation (6%), headache (5%), and diarrhea (2%).